I would look very carefully at the motivations behind this study and the methodology.
I read everything there is to know about it and there is nothing that I read which indicated that they canned the trial prematurely. Everyone did agree that there was no actual safety issue. I do know that many people thought they should NOT have suspended the trial at all.
First, I would consider that this is, as others said, not a cure but a therapy. Still, the 50% reduction in reduced hand pain benefit is likely why we are down today. Some points:
* Given that it is still somewhat effective 12 months out, for a 20 minute procedure per hand, is something to celebrate.
* I might be reaching here, but maybe the hand pain goes up as people use their hands more? The significant reduction is ONLY in hand pain, not in any of the other measures. Something to think about.
Personally, the idea of the procedure (basically injection directly into the fingers) seems a bit gross/uncomfortable to me, but it gives these patients many months of reduced pain and validates the technology.
Full disclosure: I currently have no position in CYTX stock, but may initiate a position within 1-2 weeks.
I don't agree with your logic, but the 5 down thumbs is cultish. The same people who gave you down thumbs will tell you that the person presenting means the stock is a home run because they already know the results.
So they weren't 0 before you read the press release for a 2 and a half year old study, but they are 0 now. Interesting.
The question isn't the data from these 8500 patients, but the data from the patients in the trial, which is only a couple of handfuls. Unless the results are a blowout, you can't compare 8500 patients to a dozen and have any sort of statistically significant result.